Drug Profile
Perakizumab
Alternative Names: huMAb IL-17; RG 4934; RO 5310074Latest Information Update: 31 Jul 2012
Price :
$50
*
At a glance
- Originator Roche
- Class Antirheumatics; Monoclonal antibodies
- Mechanism of Action IL17A protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Psoriatic arthritis
Most Recent Events
- 26 Jul 2012 Discontinued - Phase-I for Psoriatic arthritis in Australia (IV)
- 26 Jul 2012 Discontinued - Phase-I for Psoriatic arthritis in USA (IV)
- 28 Feb 2011 Phase-I clinical trials in Psoriatic arthritis in USA (IV)